1. Home
  2. LPTX vs AMZE Comparison

LPTX vs AMZE Comparison

Compare LPTX & AMZE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPTX
  • AMZE
  • Stock Information
  • Founded
  • LPTX 2011
  • AMZE 2019
  • Country
  • LPTX United States
  • AMZE United States
  • Employees
  • LPTX N/A
  • AMZE N/A
  • Industry
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • AMZE Beverages (Production/Distribution)
  • Sector
  • LPTX Health Care
  • AMZE Consumer Staples
  • Exchange
  • LPTX Nasdaq
  • AMZE Nasdaq
  • Market Cap
  • LPTX 11.1M
  • AMZE 12.3M
  • IPO Year
  • LPTX N/A
  • AMZE 2021
  • Fundamental
  • Price
  • LPTX $0.75
  • AMZE N/A
  • Analyst Decision
  • LPTX Hold
  • AMZE
  • Analyst Count
  • LPTX 1
  • AMZE 0
  • Target Price
  • LPTX N/A
  • AMZE N/A
  • AVG Volume (30 Days)
  • LPTX 7.6M
  • AMZE 133.0K
  • Earning Date
  • LPTX 11-12-2025
  • AMZE 11-13-2025
  • Dividend Yield
  • LPTX N/A
  • AMZE N/A
  • EPS Growth
  • LPTX N/A
  • AMZE N/A
  • EPS
  • LPTX N/A
  • AMZE N/A
  • Revenue
  • LPTX N/A
  • AMZE $1,054,111.00
  • Revenue This Year
  • LPTX N/A
  • AMZE $6,741.66
  • Revenue Next Year
  • LPTX N/A
  • AMZE $100.61
  • P/E Ratio
  • LPTX N/A
  • AMZE N/A
  • Revenue Growth
  • LPTX N/A
  • AMZE N/A
  • 52 Week Low
  • LPTX $0.22
  • AMZE $1.57
  • 52 Week High
  • LPTX $4.79
  • AMZE $28.72
  • Technical
  • Relative Strength Index (RSI)
  • LPTX 63.63
  • AMZE 40.04
  • Support Level
  • LPTX $0.46
  • AMZE $1.96
  • Resistance Level
  • LPTX $0.98
  • AMZE $2.23
  • Average True Range (ATR)
  • LPTX 0.11
  • AMZE 0.50
  • MACD
  • LPTX 0.03
  • AMZE -0.04
  • Stochastic Oscillator
  • LPTX 51.58
  • AMZE 22.32

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.

About AMZE Amaze Holdings Inc. Common Stock

Amaze Holdings Inc is engaged in producer of low carb, low calorie, premium wines in the United States. The company offers bold, crisp, and creamy wines that embody health, warmth, and a deeper connection to wellness and an active lifestyle. The company currently sell seven proprietary varietals: Cabernet Sauvignon, Pinot Noir, Chardonnay, Sauvignon Blanc, Rose, Sparkling Rose, and a limited Reserve Napa Cabernet Sauvignon.

Share on Social Networks: